Folgen
Sharon M Moe
Sharon M Moe
Professor of Medicine, Indiana University
Bestätigte E-Mail-Adresse bei iu.edu
Titel
Zitiert von
Zitiert von
Jahr
Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
S Moe, T Drüeke, J Cunningham, W Goodman, K Martin, K Olgaard, S Ott, ...
Kidney international 69 (11), 1945-1953, 2006
23022006
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
GA Block, KJ Martin, ALM De Francisco, SA Turner, MM Avram, ...
New England Journal of Medicine 350 (15), 1516-1525, 2004
14212004
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
M Ketteler, GA Block, P Evenepoel, M Fukagawa, CA Herzog, L McCann, ...
Kidney international 92 (1), 26-36, 2017
10292017
Pathophysiology of vascular calcification in chronic kidney disease
SM Moe, NX Chen
Circulation research 95 (6), 560-567, 2004
7002004
Mechanisms of vascular calcification in chronic kidney disease
SM Moe, NX Chen
Journal of the American Society of Nephrology 19 (2), 213-216, 2008
6632008
Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins
SM Moe, KD O'Neill, D Duan, S Ahmed, NX Chen, SB Leapman, ...
Kidney international 61 (2), 638-647, 2002
6262002
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease
SM Moe, MP Zidehsarai, MA Chambers, LA Jackman, JS Radcliffe, ...
Clinical Journal of the American Society of Nephrology 6 (2), 257-264, 2011
6192011
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD)
SM Moe, M Reslerova, M Ketteler, K O'neill, D Duan, J Koczman, ...
Kidney international 67 (6), 2295-2304, 2005
5222005
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States
RE LaClair, RN Hellman, SL Karp, M Kraus, S Ofner, Q Li, KL Graves, ...
American Journal of Kidney Diseases 45 (6), 1026-1033, 2005
5152005
Disorders involving calcium, phosphorus, and magnesium
SM Moe
Primary Care: Clinics in Office Practice 35 (2), 215-237, 2008
5022008
Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl
SM Moe, GM Chertow, JW Coburn, LD Quarles, WG Goodman, GA Block, ...
Kidney international 67 (2), 760-771, 2005
4512005
Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells
NX Chen, KD O'Neill, D Duan, SM Moe
Kidney international 62 (5), 1724-1731, 2002
4482002
Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels
SM Moe, D Duan, BP Doehle, KD O'Neill, NX Chen
Kidney international 63 (3), 1003-1011, 2003
4462003
Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And …
FC Brosius III, TH Hostetter, E Kelepouris, MM Mitsnefes, SM Moe, ...
Circulation 114 (10), 1083-1087, 2006
4342006
Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving …
S Moe
Kidney Int 69, 1945-1953, 2006
4152006
Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes 2017 clinical …
M Ketteler, GA Block, P Evenepoel, M Fukagawa, CA Herzog, L McCann, ...
Annals of internal medicine 168 (6), 422-430, 2018
3562018
Chronic kidney disease–mineral-bone disorder: a new paradigm
SM Moe, T Drüeke, N Lameire, G Eknoyan
Advances in chronic kidney disease 14 (1), 3-12, 2007
3502007
Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block, R Correa-Rotter, ...
Circulation 132 (1), 27-39, 2015
3112015
Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells
S Ahmed, AF Hood, AP Evan, SM Moe
American journal of kidney diseases 37 (6), 1267-1276, 2001
3062001
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease
KM Hill, BR Martin, ME Wastney, GP McCabe, SM Moe, CM Weaver, ...
Kidney international 83 (5), 959-966, 2013
3022013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20